{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# QA pair extraction from a given text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from llama_index.llms.openai import OpenAI\n",
    "from llama_index.core.schema import MetadataMode\n",
    "from llama_index.core import VectorStoreIndex, SimpleDirectoryReader\n",
    "\n",
    "from llama_index.core.extractors import (\n",
    "    SummaryExtractor,\n",
    "    QuestionsAnsweredExtractor,\n",
    ")\n",
    "from llama_index.core.node_parser import TokenTextSplitter\n",
    "from llama_index.core.ingestion import IngestionPipeline\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "import nest_asyncio\n",
    "\n",
    "nest_asyncio.apply()\n",
    "\n",
    "load_dotenv()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "llm = OpenAI(temperature=0.0, model=\"gpt-4o-mini\")\n",
    "# llm = OpenAI(temperature=0.0, model=\"gpt-4o-mini\", max_tokens=512)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "documents_txt = SimpleDirectoryReader(\"data/txt/full_text\").load_data()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "custom_prompt_template = \"\"\"\\\n",
    "Here is the context:\n",
    "{context_str}\n",
    "\n",
    "Given the contextual information, \\\n",
    "generate {num_questions} questions this context can provide \\\n",
    "specific answers to which are unlikely to be found elsewhere.\n",
    "\n",
    "Higher-level summaries of surrounding context may be provided \\\n",
    "as well. Try using these summaries to generate better questions \\\n",
    "that this context can answer.\n",
    "\n",
    "Please return the question-answer pairs, summary, key topics, entities, and findings in json format.\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "extractors_1 = [\n",
    "    QuestionsAnsweredExtractor(\n",
    "        questions=3,\n",
    "        llm=llm,\n",
    "        metadata_mode=MetadataMode.EMBED,\n",
    "        prompt_template=custom_prompt_template,\n",
    "    ),\n",
    "]\n",
    "\n",
    "\n",
    "extractors_2 = [\n",
    "    SummaryExtractor(summaries=[\"prev\", \"self\", \"next\"], llm=llm),\n",
    "    QuestionsAnsweredExtractor(\n",
    "        questions=3,\n",
    "        llm=llm,\n",
    "        metadata_mode=MetadataMode.EMBED,\n",
    "        prompt_template=custom_prompt_template,\n",
    "    ),\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 29/29 [00:28<00:00,  1.01it/s]\n",
      "100%|██████████| 29/29 [00:37<00:00,  1.31s/it]\n"
     ]
    }
   ],
   "source": [
    "\n",
    "node_parser = TokenTextSplitter(\n",
    "    separator=\" \", chunk_size=512, chunk_overlap=128\n",
    ")\n",
    "nodes = node_parser.get_nodes_from_documents(documents_txt)\n",
    "\n",
    "\n",
    "# process nodes with metadata extractors\n",
    "# pipeline = IngestionPipeline(transformations=[node_parser, *extractors_1])\n",
    "pipeline = IngestionPipeline(transformations=[node_parser, *extractors_2])\n",
    "\n",
    "nodes_1 = pipeline.run(nodes=nodes, in_place=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Excerpt from document]\n",
      "file_path: c:\\Users\\ray\\Desktop\\src\\leetcode\\rag\\data\\txt\\full_text\\medical_full_text.txt\n",
      "file_name: medical_full_text.txt\n",
      "file_type: text/plain\n",
      "file_size: 37452\n",
      "creation_date: 2024-09-17\n",
      "last_modified_date: 2024-09-17\n",
      "next_section_summary: The section discusses a clinical trial evaluating the efficacy of dapagliflozin in patients with chronic kidney disease (CKD). Key findings include:\n",
      "\n",
      "- **Trial Results**: Over a median follow-up of 2.4 years, dapagliflozin significantly reduced the occurrence of primary outcome events compared to placebo, with a hazard ratio of 0.61. The number needed to treat to prevent one primary outcome event was 19.\n",
      "- **Composite Outcomes**: Dapagliflozin showed a lower risk for a sustained decline in estimated glomerular filtration rate (GFR), end-stage kidney disease, and death from renal causes (hazard ratio 0.56). It also reduced the risk of death from cardiovascular causes or hospitalization for heart failure (hazard ratio 0.71).\n",
      "- **Mortality Rates**: Death occurred in 4.7% of the dapagliflozin group versus 6.8% in the placebo group, indicating a significant reduction in mortality risk (hazard ratio 0.69).\n",
      "- **Safety Profile**: The known safety profile of dapagliflozin was confirmed throughout the trial.\n",
      "- **Conclusion**: Dapagliflozin is effective in reducing the risk of serious kidney and cardiovascular outcomes in CKD patients, regardless of diabetes status.\n",
      "\n",
      "**Entities**:\n",
      "- **Drug**: Dapagliflozin\n",
      "- **Condition**: Chronic Kidney Disease (CKD)\n",
      "- **Sponsor**: AstraZeneca\n",
      "- **ClinicalTrials.gov Identifier**: NCT03036150\n",
      "\n",
      "Overall, the findings support the use of dapagliflozin in managing chronic kidney disease and highlight its benefits in reducing adverse outcomes.\n",
      "section_summary: **Summary:**\n",
      "\n",
      "The section discusses a clinical trial investigating the effects of dapagliflozin on patients with chronic kidney disease (CKD). Key topics and entities include:\n",
      "\n",
      "- **Study Title:** Dapagliflozin in Patients with Chronic Kidney Disease\n",
      "- **Authors:** A group of medical professionals including Hiddo J.L. Heerspink, M.D., and others involved in the DAPA-CKD Trial.\n",
      "- **Background:** Chronic kidney disease patients face high risks of adverse kidney and cardiovascular outcomes, and the impact of dapagliflozin in this population is unclear.\n",
      "- **Methods:** The trial involved 4304 participants with an estimated glomerular filtration rate (GFR) of 25 to 75 ml/min/1.73 m² and a urinary albumin-to-creatinine ratio of 200 to 5000. Participants were randomly assigned to receive either dapagliflozin (10 mg daily) or a placebo, with the primary outcome being a composite of significant decline in GFR, end-stage kidney disease, or death from renal or cardiovascular causes.\n",
      "- **Results:** The trial was stopped early due to efficacy. Over a median follow-up of 2.4 years, the dapagliflozin group had a lower incidence of primary outcome events (9.2%) compared to the placebo group (14.5%), resulting in a hazard ratio of 0.61, indicating a significant benefit of dapagliflozin in preventing adverse outcomes in CKD patients. The number needed to treat to prevent one primary outcome event was 19.\n",
      "\n",
      "This summary highlights the trial's purpose, methodology, and significant findings regarding the efficacy of dapagliflozin in CKD patients.\n",
      "questions_this_excerpt_can_answer: ```json\n",
      "{\n",
      "  \"summary\": \"The section discusses a clinical trial investigating the effects of dapagliflozin on patients with chronic kidney disease (CKD). Key topics and entities include the study's purpose, methodology, and significant findings regarding the efficacy of dapagliflozin in CKD patients.\",\n",
      "  \"key_topics\": [\n",
      "    \"Dapagliflozin\",\n",
      "    \"Chronic Kidney Disease (CKD)\",\n",
      "    \"Clinical Trial\",\n",
      "    \"Efficacy\",\n",
      "    \"Mortality Rates\",\n",
      "    \"Safety Profile\"\n",
      "  ],\n",
      "  \"entities\": {\n",
      "    \"Drug\": \"Dapagliflozin\",\n",
      "    \"Condition\": \"Chronic Kidney Disease (CKD)\",\n",
      "    \"Sponsor\": \"AstraZeneca\",\n",
      "    \"ClinicalTrials.gov Identifier\": \"NCT03036150\"\n",
      "  },\n",
      "  \"findings\": {\n",
      "    \"Trial Results\": \"Dapagliflozin significantly reduced the occurrence of primary outcome events compared to placebo, with a hazard ratio of 0.61.\",\n",
      "    \"Composite Outcomes\": \"Lower risk for sustained decline in GFR, end-stage kidney disease, and death from renal causes (hazard ratio 0.56).\",\n",
      "    \"Mortality Rates\": \"Death occurred in 4.7% of the dapagliflozin group versus 6.8% in the placebo group (hazard ratio 0.69).\",\n",
      "    \"Safety Profile\": \"The known safety profile of dapagliflozin was confirmed throughout the trial.\",\n",
      "    \"Conclusion\": \"Dapagliflozin is effective in reducing the risk of serious kidney and cardiovascular outcomes in CKD patients.\"\n",
      "  },\n",
      "  \"questions\": [\n",
      "    {\n",
      "      \"question\": \"What was the primary outcome of the clinical trial evaluating dapagliflozin in CKD patients?\",\n",
      "      \"answer\": \"The primary outcome was a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes.\"\n",
      "    },\n",
      "    {\n",
      "      \"question\": \"What was the hazard ratio for the primary outcome events in the dapagliflozin group compared to the placebo group?\",\n",
      "      \"answer\": \"The hazard ratio for the primary outcome events in the dapagliflozin group compared to the placebo group was 0.61.\"\n",
      "    },\n",
      "    {\n",
      "      \"question\": \"What was the number needed to treat (NNT) to prevent one primary outcome event in the trial?\",\n",
      "      \"answer\": \"The number needed to treat to prevent one primary outcome event was 19.\"\n",
      "    }\n",
      "  ]\n",
      "}\n",
      "```\n",
      "Excerpt:\n",
      "-----\n",
      "Dapagliflozin in Patients with Chronic Kidney Disease\n",
      "\n",
      "Hiddo J.L. Heerspink, Ph.D., Bergur V. Stefánsson, M.D., \n",
      "Ricardo Correa-Rotter, M.D., Glenn M. Chertow, M.D., Tom Greene, Ph.D., \n",
      "Fan-Fan Hou, M.D., Johannes F.E. Mann, M.D., John J.V. McMurray, M.D., \n",
      "Magnus Lindberg, M.Sc., Peter Rossing, M.D., C. David Sjöström, M.D., \n",
      "Roberto D. Toto, M.D., Anna-Maria Langkilde, M.D., and David C. Wheeler, M.D., \n",
      "for the DAPA-CKD Trial Committees and Investigators*\n",
      "\n",
      "BACKGROUND\n",
      "Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney \n",
      "disease, with or without type 2 diabetes, is not known\n",
      "\n",
      "\n",
      "METHODS\n",
      "We randomly assigned 4304 participants with an estimated glomerular filtration \n",
      "rate (GFR) of 25 to 75 ml per minute per 1.73 m2\n",
      " of body-surface area and a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 200 to 5000 to receive dapagliflozin (10 mg once \n",
      "daily) or placebo. The primary outcome was a composite of a sustained decline in \n",
      "the estimated GFR of at least 50%, end-stage kidney disease, or death from renal \n",
      "or cardiovascular causes\n",
      "\n",
      "\n",
      "RESULTS\n",
      "The independent data monitoring committee recommended stopping the trial \n",
      "because of efficacy. Over a median of 2.4 years, a primary outcome event occurred \n",
      "in 197 of 2152 participants (9.2%) in the dapagliflozin group and 312 of 2152 (14.5%) in the placebo group (hazard ratio, 0.61; 95% confidence interval \n",
      "[CI], 0.51 to 0.72; P<0.001; number needed to treat to prevent one primary outcome \n",
      "event, 19 [95% CI, 15 to 27]). The hazard ratio for the composite\n",
      "-----\n"
     ]
    }
   ],
   "source": [
    "print(nodes_1[0].get_content(metadata_mode=\"all\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Excerpt from document]\n",
      "file_path: c:\\Users\\ray\\Desktop\\src\\leetcode\\rag\\data\\txt\\full_text\\medical_full_text.txt\n",
      "file_name: medical_full_text.txt\n",
      "file_type: text/plain\n",
      "file_size: 37452\n",
      "creation_date: 2024-09-17\n",
      "last_modified_date: 2024-09-17\n",
      "prev_section_summary: **Summary:**\n",
      "\n",
      "The section discusses a clinical trial investigating the effects of dapagliflozin on patients with chronic kidney disease (CKD). Key topics and entities include:\n",
      "\n",
      "- **Study Title:** Dapagliflozin in Patients with Chronic Kidney Disease\n",
      "- **Authors:** A group of medical professionals including Hiddo J.L. Heerspink, M.D., and others involved in the DAPA-CKD Trial.\n",
      "- **Background:** Chronic kidney disease patients face high risks of adverse kidney and cardiovascular outcomes, and the impact of dapagliflozin in this population is unclear.\n",
      "- **Methods:** The trial involved 4304 participants with an estimated glomerular filtration rate (GFR) of 25 to 75 ml/min/1.73 m² and a urinary albumin-to-creatinine ratio of 200 to 5000. Participants were randomly assigned to receive either dapagliflozin (10 mg daily) or a placebo, with the primary outcome being a composite of significant decline in GFR, end-stage kidney disease, or death from renal or cardiovascular causes.\n",
      "- **Results:** The trial was stopped early due to efficacy. Over a median follow-up of 2.4 years, the dapagliflozin group had a lower incidence of primary outcome events (9.2%) compared to the placebo group (14.5%), resulting in a hazard ratio of 0.61, indicating a significant benefit of dapagliflozin in preventing adverse outcomes in CKD patients. The number needed to treat to prevent one primary outcome event was 19.\n",
      "\n",
      "This summary highlights the trial's purpose, methodology, and significant findings regarding the efficacy of dapagliflozin in CKD patients.\n",
      "next_section_summary: The section discusses a clinical trial evaluating the effects of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on patients with chronic kidney disease (CKD). Key findings indicate that dapagliflozin significantly reduces the risk of a composite outcome involving a sustained decline in estimated glomerular filtration rate (GFR), end-stage kidney disease, or death from renal or cardiovascular causes compared to a placebo. The trial was funded by AstraZeneca and registered under ClinicalTrials.gov number NCT03036150.\n",
      "\n",
      "The text highlights the global prevalence of chronic kidney disease, affecting nearly 700 million individuals, and emphasizes the condition's impact on quality of life and life expectancy. It notes the limited number of clinical trials conducted for kidney diseases compared to other medical conditions, despite the availability of simple tests for identifying impaired kidney function. Historically, the only medications shown to slow kidney function decline were angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), primarily studied in patients with type 2 diabetes.\n",
      "\n",
      "The trial's design and oversight involved an executive committee and independent monitoring to ensure participant safety, with all participants providing informed consent. The manuscript detailing the trial's findings was collaboratively written and revised by the authors involved. \n",
      "\n",
      "Key Topics:\n",
      "- Dapagliflozin and its effects on chronic kidney disease\n",
      "- Clinical trial design and oversight\n",
      "- Prevalence and impact of chronic kidney disease\n",
      "- Historical treatments for kidney function decline\n",
      "\n",
      "Key Entities:\n",
      "- Dapagliflozin\n",
      "- AstraZeneca\n",
      "- Chronic Kidney Disease (CKD)\n",
      "- Sodium-glucose cotransporter 2 (SGLT2) inhibitors\n",
      "- Angiotensin-converting enzyme (ACE) inhibitors\n",
      "- Angiotensin receptor blockers (ARBs)\n",
      "- ClinicalTrials.gov (NCT03036150)\n",
      "- University Medical Center Groningen\n",
      "section_summary: The section discusses a clinical trial evaluating the efficacy of dapagliflozin in patients with chronic kidney disease (CKD). Key findings include:\n",
      "\n",
      "- **Trial Results**: Over a median follow-up of 2.4 years, dapagliflozin significantly reduced the occurrence of primary outcome events compared to placebo, with a hazard ratio of 0.61. The number needed to treat to prevent one primary outcome event was 19.\n",
      "- **Composite Outcomes**: Dapagliflozin showed a lower risk for a sustained decline in estimated glomerular filtration rate (GFR), end-stage kidney disease, and death from renal causes (hazard ratio 0.56). It also reduced the risk of death from cardiovascular causes or hospitalization for heart failure (hazard ratio 0.71).\n",
      "- **Mortality Rates**: Death occurred in 4.7% of the dapagliflozin group versus 6.8% in the placebo group, indicating a significant reduction in mortality risk (hazard ratio 0.69).\n",
      "- **Safety Profile**: The known safety profile of dapagliflozin was confirmed throughout the trial.\n",
      "- **Conclusion**: Dapagliflozin is effective in reducing the risk of serious kidney and cardiovascular outcomes in CKD patients, regardless of diabetes status.\n",
      "\n",
      "**Entities**:\n",
      "- **Drug**: Dapagliflozin\n",
      "- **Condition**: Chronic Kidney Disease (CKD)\n",
      "- **Sponsor**: AstraZeneca\n",
      "- **ClinicalTrials.gov Identifier**: NCT03036150\n",
      "\n",
      "Overall, the findings support the use of dapagliflozin in managing chronic kidney disease and highlight its benefits in reducing adverse outcomes.\n",
      "questions_this_excerpt_can_answer: ```json\n",
      "{\n",
      "  \"summary\": \"The section discusses a clinical trial evaluating the efficacy of dapagliflozin in patients with chronic kidney disease (CKD). Key findings include significant reductions in primary outcome events, mortality rates, and the safety profile of dapagliflozin, confirming its effectiveness in managing CKD regardless of diabetes status.\",\n",
      "  \"key_topics\": [\n",
      "    \"Dapagliflozin and its effects on chronic kidney disease\",\n",
      "    \"Clinical trial design and oversight\",\n",
      "    \"Prevalence and impact of chronic kidney disease\",\n",
      "    \"Historical treatments for kidney function decline\"\n",
      "  ],\n",
      "  \"entities\": [\n",
      "    \"Dapagliflozin\",\n",
      "    \"AstraZeneca\",\n",
      "    \"Chronic Kidney Disease (CKD)\",\n",
      "    \"Sodium-glucose cotransporter 2 (SGLT2) inhibitors\",\n",
      "    \"Angiotensin-converting enzyme (ACE) inhibitors\",\n",
      "    \"Angiotensin receptor blockers (ARBs)\",\n",
      "    \"ClinicalTrials.gov (NCT03036150)\",\n",
      "    \"University Medical Center Groningen\"\n",
      "  ],\n",
      "  \"findings\": {\n",
      "    \"trial_results\": {\n",
      "      \"primary_outcome_events\": {\n",
      "        \"dapagliflozin_group\": \"9.2%\",\n",
      "        \"placebo_group\": \"14.5%\",\n",
      "        \"hazard_ratio\": 0.61,\n",
      "        \"number_needed_to_treat\": 19\n",
      "      },\n",
      "      \"composite_outcomes\": {\n",
      "        \"sustained_decline_in_GFR\": {\n",
      "          \"hazard_ratio\": 0.56\n",
      "        },\n",
      "        \"death_from_cardiovascular_causes\": {\n",
      "          \"hazard_ratio\": 0.71\n",
      "        }\n",
      "      },\n",
      "      \"mortality_rates\": {\n",
      "        \"dapagliflozin_group\": \"4.7%\",\n",
      "        \"placebo_group\": \"6.8%\",\n",
      "        \"hazard_ratio\": 0.69\n",
      "      },\n",
      "      \"safety_profile\": \"Confirmed throughout the trial\"\n",
      "    },\n",
      "    \"conclusion\": \"Dapagliflozin is effective in reducing the risk of serious kidney and cardiovascular outcomes in CKD patients, regardless of diabetes status.\"\n",
      "  },\n",
      "  \"questions\": [\n",
      "    {\n",
      "      \"question\": \"What was the hazard ratio for the primary outcome events in the dapagliflozin group compared to the placebo group?\",\n",
      "      \"answer\": \"The hazard ratio for the primary outcome events in the dapagliflozin group compared to the placebo group was 0.61.\"\n",
      "    },\n",
      "    {\n",
      "      \"question\": \"What was the number needed to treat (NNT) to prevent one primary outcome event in the trial?\",\n",
      "      \"answer\": \"The number needed to treat to prevent one primary outcome event was 19.\"\n",
      "    },\n",
      "    {\n",
      "      \"question\": \"How did dapagliflozin affect mortality rates compared to placebo in the trial?\",\n",
      "      \"answer\": \"Death occurred in 4.7% of the dapagliflozin group versus 6.8% in the placebo group, indicating a significant reduction in mortality risk with a hazard ratio of 0.69.\"\n",
      "    }\n",
      "  ]\n",
      "}\n",
      "```\n",
      "Excerpt:\n",
      "-----\n",
      "stopping the trial \n",
      "because of efficacy. Over a median of 2.4 years, a primary outcome event occurred \n",
      "in 197 of 2152 participants (9.2%) in the dapagliflozin group and 312 of 2152 (14.5%) in the placebo group (hazard ratio, 0.61; 95% confidence interval \n",
      "[CI], 0.51 to 0.72; P<0.001; number needed to treat to prevent one primary outcome \n",
      "event, 19 [95% CI, 15 to 27]). The hazard ratio for the composite of a sustained \n",
      "decline in the estimated GFR of at least 50%, end-stage kidney disease, or death \n",
      "from renal causes was 0.56 (95% CI, 0.45 to 0.68; P<0.001), and the hazard ratio \n",
      "for the composite of death from cardiovascular causes or hospitalization for heart \n",
      "failure was 0.71 (95% CI, 0.55 to 0.92; P=0.009). Death occurred in 101 participants \n",
      "(4.7%) in the dapagliflozin group and 146 participants (6.8%) in the placebo group \n",
      "(hazard ratio, 0.69; 95% CI, 0.53 to 0.88; P=0.004). The effects of dapagliflozin \n",
      "were similar in participants with type 2 diabetes and in those without type 2 diabetes. The known safety profile of dapagliflozin was confirmed.\n",
      "\n",
      "\n",
      "CONCLUSION\n",
      "Among patients with chronic kidney disease, regardless of the presence or absence \n",
      "of diabetes, the risk of a composite of a sustained decline in the estimated GFR of \n",
      "at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes \n",
      "was significantly lower with dapagliflozin than with placebo. (Funded by AstraZeneca; DAPA-CKD ClinicalTrials.gov number, NCT03036150.)\n",
      "\n",
      "\n",
      " \n",
      " \n",
      " \n",
      "ORLDWIDE\n",
      "ESTIMATES\n",
      "INDICATE\n",
      "W\n",
      "tries from February 2, 2017, through June 12,\n",
      "that nearly 700 million persons have\n",
      "2020. An executive committee consisting of nine\n",
      "chronic kidney\n",
      "-----\n"
     ]
    }
   ],
   "source": [
    "print(nodes_1[1].get_content(metadata_mode=\"all\"))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "# output text to txt files\n",
    "for i, node in enumerate(nodes_1):\n",
    "    with open(f\"output/{i}.txt\", \"w\", encoding=\"utf-8\") as f:\n",
    "        f.write(node.get_content(metadata_mode=\"all\"))  # get full text with metadata\n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
